261 related articles for article (PubMed ID: 9923973)
1. Biochemical characterization of in vivo alkylating agent resistance of a murine EMT-6 mammary carcinoma. Implication for systemic involvement in the resistance phenotype.
Chen G; Teicher BA; Frei E
Cancer Biochem Biophys; 1998 Jun; 16(1-2):139-55. PubMed ID: 9923973
[TBL] [Abstract][Full Text] [Related]
2. Enhanced expressions of glucose-6-phosphate dehydrogenase and cytosolic aldehyde dehydrogenase and elevation of reduced glutathione level in cyclophosphamide-resistant human leukemia cells.
Tsukamoto N; Chen J; Yoshida A
Blood Cells Mol Dis; 1998 Jun; 24(2):231-8. PubMed ID: 9714700
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.
Teicher BA; Ikebe M; Ara G; Keyes SR; Herbst RS
In Vivo; 1997; 11(6):463-72. PubMed ID: 9509296
[TBL] [Abstract][Full Text] [Related]
4. Comparison of mouse and human colon tumors with regard to phase I and phase II drug-metabolizing enzyme systems.
Massaad L; de Waziers I; Ribrag V; Janot F; Beaune PH; Morizet J; Gouyette A; Chabot GG
Cancer Res; 1992 Dec; 52(23):6567-75. PubMed ID: 1423302
[TBL] [Abstract][Full Text] [Related]
5. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
Caffrey PB; Zhang Y; Frenkel GD
Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
[TBL] [Abstract][Full Text] [Related]
6. Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer.
Tanner B; Hengstler JG; Dietrich B; Henrich M; Steinberg P; Weikel W; Meinert R; Kaina B; Oesch F; Knapstein PG
Gynecol Oncol; 1997 Apr; 65(1):54-62. PubMed ID: 9103391
[TBL] [Abstract][Full Text] [Related]
7. The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
Majumder S; Dutta P; Mookerjee A; Choudhuri SK
Chem Biol Interact; 2006 Feb; 159(2):90-103. PubMed ID: 16289015
[TBL] [Abstract][Full Text] [Related]
8. In-transit melanoma: the role of alkylating-agent resistance in regional therapy.
Grubbs EG; Abdel-Wahab O; Cheng TY; Abdel-Wahab Z; Peterson B; Pruitt SK; Colvin OM; Friedman HS; Tyler DS
J Am Coll Surg; 2004 Sep; 199(3):419-27. PubMed ID: 15325612
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo.
Wang X; Zhang J; Xu T
Toxicol Appl Pharmacol; 2007 Jan; 218(1):88-95. PubMed ID: 17156807
[TBL] [Abstract][Full Text] [Related]
10. [Screening of principal enzymes involved in the metabolism of anticancer drugs in human and murine colonic tumors].
Massaad L; de Waziers I; Ribrag V; Janot F; Morizet J; Beaune PH; Gouyette A; Chabot GG
Bull Cancer; 1993 May; 80(5):397-407. PubMed ID: 8173193
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide resistance in medulloblastoma.
Friedman HS; Colvin OM; Kaufmann SH; Ludeman SM; Bullock N; Bigner DD; Griffith OW
Cancer Res; 1992 Oct; 52(19):5373-8. PubMed ID: 1356617
[TBL] [Abstract][Full Text] [Related]
12. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
Geroni C; Marchini S; Cozzi P; Galliera E; Ragg E; Colombo T; Battaglia R; Howard M; D'Incalci M; Broggini M
Cancer Res; 2002 Apr; 62(8):2332-6. PubMed ID: 11956092
[TBL] [Abstract][Full Text] [Related]
13. Characterization of L5178Y murine lymphoblasts resistant to quinone antitumor agents.
Begleiter A; Leith MK; McClarty G; Beenken S; Goldenberg GJ; Wright JA
Cancer Res; 1988 Apr; 48(7):1727-35. PubMed ID: 3127038
[TBL] [Abstract][Full Text] [Related]
14. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
[TBL] [Abstract][Full Text] [Related]
15. Human renal UOK130 tumor cells: a drug resistant cell line with highly selective over-expression of glutathione S-transferase-pi isozyme.
Wang W; Liu G; Zheng J
Eur J Pharmacol; 2007 Jul; 568(1-3):61-7. PubMed ID: 17509556
[TBL] [Abstract][Full Text] [Related]
16. [Biochemical mechanisms of resistance to a new antineoplastic agent amin(cyclopeptidylamin)-S-(-)-malatoplatinum (II) (cycloplatam)].
Dederer LIu; Lankin VZ; Konovalova AL; Gorbacheva LB
Biokhimiia; 1995 Apr; 60(4):602-9. PubMed ID: 7779982
[TBL] [Abstract][Full Text] [Related]
17. Radiation resistance in a melphalan-resistant subline of a rat mammary carcinoma.
Lehnert S; Vestergaard J; Batist G; Aloui-Jamali MA
Radiat Res; 1994 Aug; 139(2):232-9. PubMed ID: 8052700
[TBL] [Abstract][Full Text] [Related]
18. Expression of a rat glutathione-S-transferase complementary DNA in rat mammary carcinoma cells: impact upon alkylator-induced toxicity.
Schecter RL; Alaoui-Jamali MA; Woo A; Fahl WE; Batist G
Cancer Res; 1993 Oct; 53(20):4900-6. PubMed ID: 8402679
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the antioxidant activities in dox-sensitive and -resistant Friend leukemia cells. Effect of doxorubicin.
Crescimanno M; D'Alessandro N; Armata MG; Toulmond S; Tapiero H
Anticancer Res; 1991; 11(2):901-3. PubMed ID: 2064348
[TBL] [Abstract][Full Text] [Related]
20. Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers alkylating drug resistance in NIH 3T3 mouse fibroblasts.
Greenbaum M; Létourneau S; Assar H; Schecter RL; Batist G; Cournoyer D
Cancer Res; 1994 Aug; 54(16):4442-7. PubMed ID: 8044793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
